title: R-CHOP versus R-COMP: are they really equally effective?
abstract: The first-line standard treatment for diffuse large B-cell lymphoma (DLBCL) is the R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone). It is associated with cardiotoxicity, which is why new treatment strategies are needed. Liposomial doxorubicin has been proven to reduce these side-effects, but until now a direct comparison regarding efficacy has not yet been published. We retrospectively assessed 364 consecutive DLBCL patients who underwent either R-CHOP (218; 60%) or R-COMP (doxorubicin replaced by non-pegylated liposomal doxorubicin; 146; 40%) in first line and compared outcome and survival. We provide evidence that both regimens induce a high and comparable number of complete remissions and that both are able to cure patients with DLBCL. Confirmatory data are needed.
authors.affiliation: Department of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria. Electronic address: m.mian@webmaxxi.eu.
authors.forename: M
authors.initials: M
authors.lastname: Mian
authors.affiliation: Department of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: I
authors.initials: I
authors.lastname: Wasle
authors.affiliation: Department of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: G
authors.initials: G
authors.lastname: Gamerith
authors.affiliation: Department of Medical Oncology, University of Messina, Messina, Italy.
authors.forename: P
authors.initials: P
authors.lastname: Mondello
authors.affiliation: 3rd Medical Department, Paracelsus Medical University Salzburg, Austria.
authors.forename: T
authors.initials: T
authors.lastname: Melchardt
authors.affiliation: Department of Internal Medicine, Hospital of Feldkirch, Feldkirch, Austria.
authors.forename: T
authors.initials: T
authors.lastname: Jäger
authors.affiliation: Department of Internal Medicine, Division of Haematology, Medical University of Graz, Austria.
authors.forename: W
authors.initials: W
authors.lastname: Linkesch
authors.affiliation: Department of Hematology & Oncology, Medical University of Innsbruck, Innsbruck, Austria.
authors.forename: M
authors.initials: M
authors.lastname: Fiegl
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011092:Polyethylene Glycols / Q000008:administration & dosage; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012189:Retrospective Studies; D000069283:Rituximab; D015996:Survival Rate; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; C571759:R-CHOP protocol; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D000069283:Rituximab; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone
keywords: Diffuse large B-cell lymphoma; R-CHOP; R-COMP; outcome